Geode Capital Management LLC Acquires Shares of 308,930 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)

Geode Capital Management LLC bought a new position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 308,930 shares of the company's stock, valued at approximately $4,774,000. Geode Capital Management LLC owned approximately 1.27% of Artiva Biotherapeutics as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of ARTV. State Street Corp acquired a new position in shares of Artiva Biotherapeutics during the third quarter worth $1,337,000. BNP Paribas Financial Markets bought a new position in Artiva Biotherapeutics during the 3rd quarter worth $42,000. Charles Schwab Investment Management Inc. acquired a new position in Artiva Biotherapeutics during the 3rd quarter worth about $623,000. Wellington Management Group LLP bought a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at about $2,912,000. Finally, RA Capital Management L.P. acquired a new stake in shares of Artiva Biotherapeutics in the third quarter valued at about $152,234,000.

Analyst Upgrades and Downgrades

ARTV has been the topic of several analyst reports. HC Wainwright initiated coverage on Artiva Biotherapeutics in a report on Monday, December 30th. They issued a "buy" rating and a $20.00 target price on the stock. Needham & Company LLC restated a "buy" rating and issued a $23.00 price target on shares of Artiva Biotherapeutics in a research report on Wednesday, November 13th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $21.00.

Artiva Biotherapeutics Stock Performance

ARTV stock traded down $0.07 during mid-day trading on Monday, reaching $10.60. The company's stock had a trading volume of 45,000 shares, compared to its average volume of 48,600. Artiva Biotherapeutics, Inc. has a 12 month low of $9.68 and a 12 month high of $17.31. The business's 50 day moving average price is $11.37.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.24). On average, research analysts predict that Artiva Biotherapeutics, Inc. will post -4.68 earnings per share for the current year.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.